Treatment of third-stage larvae of Toxocara cati with milbemycin oxime plus praziquantel tablets and emodepside plus praziquantel spot-on formulation in experimentally infected cats by Sonja Wolken et al.
ORIGINAL PAPER
Treatment of third-stage larvae of Toxocara cati with milbemycin
oxime plus praziquantel tablets and emodepside plus praziquantel
spot-on formulation in experimentally infected cats
Sonja Wolken & Claudia Böhm & Roland Schaper &
Thomas Schnieder
Received: 13 July 2012 /Accepted: 17 July 2012 /Published online: 4 August 2012
# The Author(s) 2012. This article is published with open access at Springerlink.com
Abstract Toxocara cati is the most prevalent gastrointesti-
nal helminth in cats worldwide, with cats of all ages at risk
of infection. An anthelminthic treatment that not only affects
the gut-dwelling stages of this parasite but is also effective
against developmental stages in the tissue has the advantage
that the pathology caused by migrating larvae is minimized
and the need for repeated treatments is reduced. This study
was conducted to evaluate the efficacy of milbemycin ox-
ime/praziquantel tablets (Milbemax®, Novartis) against
third-stage larvae of T. cati in comparison to a spot-on
formulation of emodepside and praziquantel (Profender®,
Bayer). Twenty-four kittens were experimentally infected
with T. cati and randomly allocated to three study groups.
Treatments were performed at the minimum therapeutic
dosage 5 days after the experimental infection. The devel-
opment of patent infections was monitored and all cats were
dewormed 50 days post-infection. Efficacies were calculat-
ed based on counts of excreted worms in the treated groups
compared to a negative control group. Seven of the eight
cats in the negative control group developed a patent T. cati
infection and all cats were excreting worms at the end of the
study (geometric mean worm count 18.1). No efficacy could
be observed for the milbemycin oxime-treated animals. All
cats developed a patent infection and excreted worms (geo-
metric mean worm count 27.7). The treatment with
Profender® was 98.5 % effective against L3 of T. cati.
One cat developed a patent infection and was excreting
worms at the end of the study (geometric mean worm count
0.3). No adverse reactions were noted in either treatment
group.
Introduction
Despite the availability of numerous highly efficacious
anthelminthic products, worm infestations remain the most
common finding in companion animals, with Toxocara cati
being the most prevalent gastrointestinal helminth in cats
worldwide. Analysis of lab data (Barutzki and Schaper
2003, 2011) in Germany showed that no significant changes
in prevalence rates have been observed over the last
12 years. These results demonstrate the constantly high need
for further efforts to control these pests and once again
illustrate the parasites' effective survival strategies.
The high reproductive rate of ascarids and the extremely
high tenacity of the eggs are major contributors to their
success story. This indicates that strategic control of these
parasites should minimize the contamination of the environ-
ment by animals that harbour patent infections. Besides this
epidemiological aspect, it is also beneficial for the individ-
ual patient to be cleared of an existing infection as soon as
possible to minimize the pathology caused by migrating
larvae. In 1956, Sprent described the tracheal migration
route of T. cati after egg ingestion and in this context
observed the occurrence of haemorrhagic spots on the lungs.
Later, it was shown that the pathological changes caused by
migrating T. cati larvae include proliferation of the intima
and media, which may result in complete occlusion of the
pulmonary arteries (Swerczek et al. 1970; Weatherley and
Hamilton 1984).
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Since then, little attention has been paid to the pathology
caused by early-migrating T. cati larvae, and currently, effi-
cacy against third-stage larvae (L3) has been demonstrated
only by one product (Profender®) (Reinemeyer et al. 2005).
Profender® is thus the only product licenced for the treat-
ment of these early stages of T. cati. Recently, the role that
parasites plays in the development of acute and chronic lung
disease in cats has been reinvestigated, and importance has
been attached not only to the more obvious lung-relevant
parasites likeDirofilaria immitis and Aelurostrongylus abstru-
sus but also to the migrating stages of T. cati (Dillon 2011).
This study aimed to evaluate and compare the efficacy of
emodepside and the macrocyclic lactone milbemycin oxime
against T. cati L3. For the latter, efficacy against gut-
dwelling fourth-stage larvae has been demonstrated
(Schenker et al. 2007), but no information is available on the
efficacy against the stage of T. cati which affects the lungs.
Materials and methods
The study was designed as a controlled, randomized and
blinded efficacy study. Wherever possible, the principles of
Good Clinical Practice (Veterinary International Conference
on Harmonization (VICH) 2000a, b, c) and the WAAVP
guideline for evaluating the efficacy of anthelmintics for
dogs and cats (Jacobs et al. 1994) were followed.
Twenty-four purpose-bred domestic short-hair kittens
(age 14–15 weeks) were acclimatized to the study facil-
ity for 7 days. During the acclimatization period, three
faecal egg counts (FECs) were performed on consecu-
tive days to demonstrate the absence of helminth infec-
tions. The kittens had never received an anthelminthic
or other drug that could have interfered with the study
objective. Fitness for study inclusion was demonstrated
by physical examinations prior to the experimental in-
fection and prior to treatment. On study day 0, all
kittens were inoculated with approximately 400 embry-
onated T. cati eggs from a strain that had been main-
tained in the lab since 2010 and was originally isolated
from a naturally infected cat in Germany.
Based on sex and body weight, the kittens were
randomly allocated on study day 4 to three study groups
with eight cats each and a sex ratio of 1:1 (Table 2).
Treatments were performed on study day 5. Group 1 was
treated with the minimum therapeutic dosage of 3 mg/kg
emodepside plus 12 mg/kg praziquantel (Profender®),
corresponding to 0.12 ml/kg spot-on solution. The com-
mercially available 0.35-ml pipette was emptied into a
glass vial and the appropriate volume was withdrawn
using a 1,000-μl pipette and applied to the cat's skin at
the base of the skull in front of the shoulder blades.
Group 2 received the minimum therapeutic dosage of
2 mg/kg milbemycin oxime and 5 mg/kg praziquantel.
The arithmetic mean weight of ten tablets of the batch
was calculated to determine the correct tablet mass per
kilogramme. Excess tablet mass was rubbed off with
sandpaper. The maximum discrepancy between target
and actual tablet weight was +0.8 mg/kg, corresponding
to +0.02 mg/kg milbemycin oxime. Group 3 was the
negative control group and was thus left untreated.
During the prepatent period, the kittens were group-
housed in their respective treatment group. Housing and
general maintenance was standardized across all ani-
mals. The cats received a commercially available dry
food (Growth™, Royal Canin) and tap water ad libitum.
General health observations were conducted daily during
cleaning and feeding activities and during social inter-
action with the animal attendants. To monitor the pos-
sible onset of patency, FECs were performed on pooled
group samples three times per week starting on study
day 25. When the first pool of sample was positive, the
cats were individually housed in cages and the number
of eggs per gram of faeces was determined daily until
the end of the study. Throughout the study, the rooms,
cages and litter trays were carefully inspected to detect
any spontaneously expelled worms. On study day 50,
all cats were dewormed with a combination product of
praziquantel and pyrantel (Drontal®) according to the
manufacturer's recommendations, and all faeces were
carefully searched for excreted worms for 3 days fol-
lowing the treatment. Worms were counted and differ-
entiated by stage and sex and total numbers were used
to calculate the product effect according to Abbot's
formula for controlled tests:
Percentage of efficacy ð%Þ ¼ 100 C  Tð Þ=C
where C was the geometric mean of T. cati in the
control group, and T was the geometric mean of T. cati
in the treated group (Profender® or Milbemax®). To
confirm the success of treatment, a final FEC was
performed on study day 54 before the study was termi-
nated. The experimental design is summarized in
Table 1.
One-way analysis of variance was used to compare the
groups with regard to pre-treatment body weights. A non-
parametric test (Mann–Whitney rank sum test) was used to
analyze worm count data and daily egg excretion.
Results
All cats stayed clinically healthy throughout the study peri-
od. Treatment in groups 1 (Profender®) and 2 (Milbemax®)
was tolerated well by all cats. Neither local nor systemic
effects were observed. There was no statistically significant
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difference between the groups regarding body weight on
study day 4 (p00.954).
On study day 36, the first positive faecal group
sample was obtained in group 3 (negative control),
and from study day 42 until the end of the study, seven
out of eight cats in this group shed Toxocara eggs. One
cat stayed coproscopically negative throughout the
study. In group 2 (Milbemax®), all cats were copros-
copically positive from study day 41 onwards. In group
1 (Profender®), seven out of eight cats stayed copros-
copically negative throughout the study. One cat began
to shed Toxocara eggs on study day 42. Where egg
excretion was concerned, there was no statistically sig-
nificant difference between group 2 (Milbemax®) and
the control group (p≥0.442). Egg counts in Profender®-
treated animals differed significantly from the control
group from study day 41 until the end of the study
(p≤0.035). After deworming at the end of the study, a
total of 257 worms was collected in the negative control
group. Worms were recovered from all eight cats, and
six cats harboured an adequate infection (≥5 worms).
The coproscopically negative cat harboured two male
worms and an immature female. In the Milbemax®-
treated group, a total of 318 worms was collected.
Worm numbers in this treatment group exceeded the
numbers in the control group; therefore, no treatment
effect was evident. There was no statistically significant
difference between the negative control group and the
Milbemax®-treated group (p00.382). The treatment in
group 1 (Profender®) was 98.5 % effective (p<0.001).
Only the coproscopically positive cat harboured six
worms (Table 2). Spontaneously expelled worms were
not detected in any group. Individual worm counts are
presented in Table 3 and the course of egg excretion is
presented in graph form in Fig. 1. The final FEC on
study day 54 was negative in all cats, demonstrating the
success of treatment.
Discussion
The efficacy of the emodepside/praziquantel spot-on solu-
tion against third-stage larva of T. cati was comparable to
the level of control obtained in the studies for marketing
authorization (Reinemeyer et al. 2005). Efficacy calcula-
tions in the study presented here were based on worm counts
after deworming and not on worm counts determined at
necropsy. Although desirable from an ethical point of view,
this procedure has disadvantages that reduce the reliability
of the results and is hence generally not acceptable in
laboratory studies for drug approval. Worms may be wholly
or partially digested when passed in the faeces and may
therefore not be identified. This fact is of lesser importance
for “strong” worms like ascarids, but can be critical for
worms that are more fragile. Further unintended loss of
worms may occur through coprophagia, mainly seen in
dogs, or ingestion of regurgitated worms as seen in dogs
and cats. Finally, only a necropsy can prove that the animal
was completely cleared of an existing worm burden. As seen
in this study, low worm burdens or infections with single-
sex worms or immature worms cannot be detected by faecal
examinations. Despite these drawbacks, it can be concluded
Table 1 Summary experimental design
Study day Activity
−7 to −1 Acclimatization, FEC over 3 consecutive days
0 Experimental infection with 400 T. cati eggs
4 Randomization and allocation to groups
5 Treatment in groups 1 and 2
25—onset of positive
group samples
Housing in groups, FEC three times a week in
groups until positive, then individual housing
49—onset of positive
group samples
FEC in individually housed cats
50 Anthelmintic treatment
51–53 Collection of worms in faeces
54 FEC
Table 2 Group details
































Parasitol Res (2012) 111:2123–2127 2125
that reliable data were generated in this study. Results
obtained in group 1 (Profender®) were similar to former
studies and the negative control group showed an ade-
quate level of infection. As is often seen in experimen-
tally infected animals, the individual worm burdens in
the negative control group were highly variable (range
3–112), but the requirement for six adequately infected
animals was fulfilled.
No efficacy could be observed in the milbemycin oxime-
treated cats. Numbers of excreted worms and eggs passed in
the faeces exceeded those in the control group. Treatment
was performed 5 days after the experimental infection to
coincide with the migrating stage of the parasite (VICH
2000c). Although information on the detailed migratory
behaviour of T. cati is scarce, observations by Sprent
(1956) showed that after egg infection, the larvae perform
a liver–lung migration and can be found in the lungs at this
time point of infection. To be effective against these early-
migrating larvae, an active ingredient has to be present at a
sufficient level within these tissues and/or the blood stream
at a certain time point. According to Reinemeyer and Court-
ney (2001), 5–10 % of an orally administered dose of
milbemycin oxime is absorbed; the major part is excreted
with the faeces. Although milbemycin oxime in the formu-
lated tablet Milbemax® is effective against migrating larval
stages of D. immitis in the cat (Genchi et al. 2004), the
results obtained under the conditions of this study lead to
the assumption that migrating T. cati larvae are not
likewise affected, either due to low drug levels or to an
unfavourable tissue distribution with regard to this para-
site. It can be concluded that to date, the spot-on formu-
lation of emodepside and praziquantel remains the only
anthelmintic with proven efficacy against migrating T.
cati larvae.
Table 3 Individual worm










1. Profender® 1 0 0 0 0 0.3
2 4 2 0 6
3 0 0 0 0
4 0 0 0 0
5 0 0 0 0
6 0 0 0 0
7 0 0 0 0
8 0 0 0 0
2. Milbemax® 1 5 2 0 7 27.7
2 6 5 0 11
3 10 22 10 42
4 9 30 7 46
5 9 13 0 22
6 55 53 27 135
7 11 7 2 20
8 17 18 0 35
3. Untreated control 1 5 6 0 11 18.1
2 7 18 0 25
3 1 2 0 3
4 1 3 0 4
5 8 6 4 18
6 50 54 8 112
7 14 27 24 65
8 5 14 0 19













Fig. 1 Arithmetic mean faecal egg count and standard deviation on the
individual study days
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